9 reports

In January 2017, Biogen initiated a Phase ## trial of an anti-tau monoclonal antibody, BIIB##, in healthy volunteers and participants with Alzheimer' s disease.

  • Antisense Technology
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Biogen Idec Inc.

GC## is a pan-specific human anti-TGF beta monoclonal antibody.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH

GC## is a pan-specific human anti-TGF beta monoclonal antibody.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH

GC## is a pan-specific human anti-TGF beta monoclonal antibody.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH
  • NUMBER OF PRODUCTS BY STAGE AND MOLECULE TYPE, H2 2017
  • DIABETIC RETINOPATHY - PIPELINE BY AERIE PHARMACEUTICALS INC, H2 2017

Monoclonal antibody acts as IAP inhibitor.

  • Antisense Technology
  • Ophthalmology
  • Therapy
  • Type 2 Diabetes
  • Product Initiative
  • NUMBER OF PRODUCTS BY STAGE AND MOLECULE TYPE, H1 2016

It is a human recombinant monoclonal antibody.

  • Antisense Technology
  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • NUMBER OF PRODUCTS BY STAGE AND MOLECULE TYPE, H1 2017

THE DRUG CANDIDATE IS A MONOCLONAL ANTIBODY.

  • Antisense Technology
  • Cell Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.

If other modalities are chosen, such as small molecules or monoclonal antibodies, Isis is eligible to receive up to USD## million in milestone payments.

  • Antisense Technology
  • United States
  • Company
  • Company Financials
  • Ionis Pharmaceuticals, Inc.

MK-## is an anti-IGF##R recombinant monoclonal antibody.

  • Antisense Technology
  • Insulin
  • Lung Cancer
  • United States
  • Product Initiative